Illinois Municipal Retirement Fund Boosts Stake in Gilead Sciences, Inc. $GILD

Illinois Municipal Retirement Fund lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 336,208 shares of the biopharmaceutical company’s stock after acquiring an additional 46,940 shares during the period. Gilead Sciences makes up 0.5% of Illinois Municipal Retirement Fund’s investment portfolio, making the stock its 25th biggest position. Illinois Municipal Retirement Fund’s holdings in Gilead Sciences were worth $37,275,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Altman Advisors Inc. grew its position in Gilead Sciences by 3.4% during the second quarter. Altman Advisors Inc. now owns 21,986 shares of the biopharmaceutical company’s stock valued at $2,456,000 after acquiring an additional 716 shares during the last quarter. Fountainhead AM LLC boosted its holdings in shares of Gilead Sciences by 2.7% during the second quarter. Fountainhead AM LLC now owns 4,519 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 118 shares during the period. Fidelis Capital Partners LLC lifted its holdings in Gilead Sciences by 12.2% in the 2nd quarter. Fidelis Capital Partners LLC now owns 5,291 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 575 shares during the period. ProShare Advisors LLC boosted its holdings in Gilead Sciences by 5.0% in the second quarter. ProShare Advisors LLC now owns 1,945,966 shares of the biopharmaceutical company’s stock valued at $215,749,000 after acquiring an additional 93,083 shares in the last quarter. Finally, Profund Advisors LLC boosted its stake in shares of Gilead Sciences by 7.9% during the 2nd quarter. Profund Advisors LLC now owns 125,947 shares of the biopharmaceutical company’s stock valued at $13,964,000 after purchasing an additional 9,252 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 71,500 shares of company stock worth $8,336,040 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a report on Friday, October 31st. TD Cowen increased their target price on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Argus lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Truist Financial reiterated a “buy” rating and set a $145.00 price target (up previously from $127.00) on shares of Gilead Sciences in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $127.82.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $118.84 on Monday. The company has a market capitalization of $147.46 billion, a P/E ratio of 23.67, a P/E/G ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm’s 50 day simple moving average is $116.49 and its two-hundred day simple moving average is $112.26. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the business posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s payout ratio is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.